Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”

SIMPLE SUMMARY: Patients with HER-2 positive breast cancer who progress through available HER2-targeted therapy, at present, have few effective treatment options. PIK3CA is mutated in approximately 20% of HER2 positive breast cancers, contributes to HER-2 therapy resistance and may be predictive of...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Cancers (Basel)
Główni autorzy: Keegan, Niamh M., Furney, Simon J., Walshe, Janice M., Gullo, Giuseppe, Kennedy, M. John, Smith, Diarmuid, McCaffrey, John, Kelly, Catherine M., Egan, Keith, Kerr, Jennifer, Given, Mark, O’Donovan, Peter, Hernando, Andres, Teiserskiene, Ausra, Parker, Imelda, Kay, Elaine, Farrelly, Angela, Carr, Aoife, Calzaferri, Giulio, McDermott, Ray, Keane, Maccon M., Grogan, Liam, Breathnach, Oscar, Morris, Patrick G., Toomey, Sinead, Hennessy, Bryan T.
Format: Artigo
Język:Inglês
Wydane: MDPI 2021
Hasła przedmiotowe:
Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7999809/
https://ncbi.nlm.nih.gov/pubmed/33799597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13061225
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy